5th Winter Conference

Medicinal and Bioorganic Chemistry

26 - 31 January 2003

  • Conference Agenda

    Sunday January 26, 2003
    1:00 pm to 5:00 pm Registration Registration packets may be picked up from 1:00 - 6:00 pm, at the Conference Registration desk located on the Ballroom level.
    4:00 to 7:00 pm Welcome Reception and Super Bowl Party
    7:00 pm Gary L. Grunewald,University of Kansas – Session Chair

    Symposium Topic 1: Round Table Discussion on the Foreseable Future of Medicinal & Bioorganic Chemistry

      Paul S. Anderson, retired VP Bristol Meyers Squibb & Company
      Lester A. Mitscher, University of Kansas
      John G. Topliss, Professor of Medicinal Chemistry, University of Michigan and formerly VP of Chemistry at Warner Lamber/Parke-Davis
    Monday, January 27, 2003  
    8:00-11.00 am Victor Snieckus,Queen's University – Session Chair

    Symposium Topic 2: C-H Activation: The New Generation

      Howard Alper, University of Ottawa Metal Catalyzed Reactions of Pharmaceutical Value
      Robert Bergman, University of California C-H Activation: The Last Generation Tries to Keep Up with the Next Generation
      John Hartwig, Yale University Catalytic Regioselective Functionalization of Alkanes and Arenes with Borane Reagents
      Victor Snieckus, Queen's University C-H Activation. An Overview
    4:00 - 5:00 pm Philippe Nantermet, Merck Research Laboratories - Session Chair

    Poster Session I

    5:00 - 8:00 pm Daniel Flynn, Deciphera Pharmaceuticals - Session Chair

    Symposium Topic 3: Chemical Genomics in Drug Discovery

      Daniel Flynn, Deciphera Pharmaceuticals Approaches and Opportunities in Chemical Genomics
      Michael Foley, Infinity Pharnaceuticals Inc Chemical Genetics
      MMark Murcko, Vertex Pharmaceuticals Inc Organizing Research by Gene Family
      Victor G. Matassa, Phd, Graffinity Fragment-Based Diversity on Chemical Microarrays - Discovery from a Different Angle
    Tuesday, January 28, 2003  
    8:00 - 11:00 am Michael Rafferty, Pfizer Global Research & Development - Session Chair

    Symposium Topic 4: New Developments in High-Throughput Screening Methodologies

      Michael Rafferty, Pfizer Global Research & Development High Throughput Pharnacolgy in Drug Discovery
      Sohail A. Qureshi, PhD, PanVera Corporation Cell-Based Assay Development Using GeneDriver
      Huw Nash, NeoGenesis Pharmaceuticals ALIS: Ultra High Capacity Affinity Screening for Drug Discovery
      Timm Jessen, Evotec OAI Increased exploitation of the chemical space through economic sensitivity screening
    5:00 - 8:00 pm Tony Barrett, Imperial College and Mike Lipton, Pharmacia Corporatilon - Session Chairs

    Symposium Topic 5: Innovations in Process & Scale-Up Chemistry

      Robert Osborne, AstraZeneca Optimisation by Design
      Shari Taghavi, CPC Germany Microreaction Technology, Innovation in Chemical Syntheses from Bench to Production
      Dennis Curran, University of Pittsburgh Fluorous Methods in Synthesis of Small Molecules
      Andy de Mello, Imperial College Microfluidic Routes to the Controlled Synthesis of Small Molecules
      Peter Wassercheid, University of Aachen, Germany Ionic Liquids – A New Concept for Synthesis in Pharmaceutical Chemistry and Fine Chemicals Productions
    Wednesday, January 29, 2003  
    8:00 - 11:00 am Michael VanNieuwenhze, University of California, San Diego - Session Chair

    Symposium Topic 6: General Papers I

    12:00 pm Mountain Lunch at Bashor Picnic Area and Group Photo
    2:00 pm NASTAR Race
    6:00 - 11:00 pm Chi-Huey Wong, The Scripps Research Institute - Keynote Speaker

    Keynote Address and Banquet

    Thursday, January 30, 2003  
    8:00 - 11:00 am Dennis Dean, Merck Research Institute - Session Chair

    Symposium Topic 7: General Papers II

    5:00 - 8:00 pm Wieslaw M. Kazmierski, GlaxoSmithKiline - Session Chair

    Symposium Topic 8: Chemokine Receptor Antagonists – HIV Targets

      Nathaniel R. Landau, Infectious Disease Laboratory, The Salk Institute for Biological Studies Fusion Inhibitors: Closing the Door on HIV
      Dr Paul Finke, Department of Medicinal Chemistry , Merck and Co The Development of Potent, Orally Active Antagonists of the Human CCR5 Receptor as Anti-HIV Agents
      Dr Hiromu Habashita, ONO Pharmaceutical Co. Ltd, Japan Medicinal Chemistry Research Laboratories The Discovery of CCR5 Antagonists from GPCR Targeted Combinatorial Library
      Dr Jay R. Tagat, Schering-Plough Research Institute The Discovery of Potent, Orally Bioavailable CCR5 Antagonists for the Potential Treatment of HIV Infection
    Friday, January 31, 2003  
    8:00 - 11:00 am Lihu Yang, Merck and Co - Session Chair

    Symposium Topic 9: Chemokine Receptor Antagonists – Inflammation Targets

      Lihu Yang, Merck and Co Chemokine Receptor Antagonism as Potential Therapeutic Targets in Inflammatory Diseases
      Karen May, Berlex Laboratories Inc Discovery of Selective, Potent, Orally Available CCR1 Receptor Antagonists"
      Huw Daview, AstraZeneca Optimization of Small Molecule CCR2b Antagonists
      Jianming Bao, Merck & Co Pyrrolidine Antagonists of the CCR3 Chemokine Receptors
      Don Hansen, Pharmacia Corporation Evolution in Our Design of Selective Inhibitors of Human Nitric Oxide Synthases from Cyclic Amidines to Hybrid Iminohomopiperidinium Amino Acid
    12:00 pm Meeting Closes